Literature DB >> 2479050

Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation.

T Kahn1, K Bürrig, B Schmitz-Dräger, J S Lewin, G Fürst, U Mödder.   

Abstract

Twenty-eight patients with prostatic carcinoma who underwent magnetic resonance (MR) imaging and subsequent radical prostatectomy were studied. The resected prostates were sectioned axially, and the whole-mount prostatic specimen was compared with the corresponding MR images. The carcinoma could be identified in 20 cases (71%), but the tumor volume was underestimated in 12 patients (43%). In 19 of 20 visualized cases (95%), the carcinoma was seen as an area of low signal intensity within the peripheral zone on T2-weighted images. However, in one case the signal intensity of the carcinoma was higher than that of the remainder of the peripheral zone. All carcinomas were located within the peripheral zone. The accuracy of MR imaging in the prediction of extraglandular tumor spread was 82%, with a sensitivity of 37.5% and a specificity of 100%. Nineteen patients (67%) exhibited histologically benign hyperplasia, which could be identified on MR images in 10 cases (53%). The signal intensities of the nodules varied. All areas of benign hyperplasia were located within the central zone. The location of the pathologic changes must therefore be considered in differential diagnosis.

Entities:  

Mesh:

Year:  1989        PMID: 2479050     DOI: 10.1148/radiology.173.3.2479050

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

Review 1.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.

Authors:  J Kurhanewicz; D B Vigneron; S J Nelson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Methods for volume assessment of prostate cancer.

Authors:  Heinz-Peter Schlemmer; Stefan Corvin
Journal:  Eur Radiol       Date:  2004-02-06       Impact factor: 5.315

3.  Reproducibility of image interpretation in MRI of the prostate: application of the sextant framework by two different radiologists.

Authors:  Ullrich Mueller-Lisse; Ulrike Mueller-Lisse; Juergen Scheidler; Gerhardt Klein; Maximilian Reiser
Journal:  Eur Radiol       Date:  2005-04-20       Impact factor: 5.315

4.  Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo.

Authors:  M Albert Thomas; Thomas Lange; S Sendhil Velan; Rajakumar Nagarajan; Steve Raman; Ana Gomez; Daniel Margolis; Stephany Swart; Raymond R Raylman; Rolf F Schulte; Peter Boesiger
Journal:  MAGMA       Date:  2008-07-17       Impact factor: 2.310

Review 5.  Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-09-01       Impact factor: 8.262

Review 6.  Primary staging of prostate cancer.

Authors:  G J Jager; J O Barentz; E T Ruijter; J J de la Rosette; G O Oosterhof
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

7.  Advances in diagnosis and management of prostate cancer.

Authors:  S L Goldenberg
Journal:  Can Fam Physician       Date:  1990-05       Impact factor: 3.275

Review 8.  Role of Multiparametric MR Imaging in Malignancies of the Urogenital Tract.

Authors:  Alberto Diaz de Leon; Daniel Costa; Ivan Pedrosa
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

Review 9.  Advances in MR spectroscopy of the prostate.

Authors:  John Kurhanewicz; Daniel B Vigneron
Journal:  Magn Reson Imaging Clin N Am       Date:  2008-11       Impact factor: 2.266

10.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume.

Authors:  Yousef Mazaheri; Hedvig Hricak; Samson W Fine; Oguz Akin; Amita Shukla-Dave; Nicole M Ishill; Chaya S Moskowitz; Joanna E Grater; Victor E Reuter; Kristen L Zakian; Karim A Touijer; Jason A Koutcher
Journal:  Radiology       Date:  2009-08       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.